Immutep (ASX: IMM) has announced a solid median overall survival (OS) rate in Cohort B of its TACTI-003 (Keynote-C34) Phase ...

Global and US biotech shares have recovered from their lows on signs that the chaos created by the Trump administration is ...

While drugmakers battle over costs, MoveSmarter Health, a U.S. startup launched in Argentina, is sidestepping the fray with a ...

Investors are sending this ASX All Ords share flying on Monday. But why? The post Guess which ASX All Ords share just ...

FDA meeting requested following Phase IIb trial showing median overall survival of 17.6 months without chemotherapy Immutep ...

U.S. drug maker Merck is building a $1 billion facility in Wilmington, Delaware, aimed at increasing domestic production of ...

Data-mining and analytics company Palantir (NYSE:PLTR) will be announcing earnings results tomorrow after market hours.